Garmin launches high-end smartwatches, FDA cracks down on tele-abortion, and more digital health briefs

Also: FDA cracks down on tele-abortion companies and Klara adds an investor.
By Jonah Comstock
Share

 

Correction: A brief originally included in this roundup, about Quip's funding, has been removed. The round in question was not new; it was previously reported here.

...

With new investor, Klara heading to market. New York-based Klara, a healthcare messaging system, has secured a new investment from Stage 2 Capital. The amount of the investment was not disclosed. Klara brought Stage 2 in to help with its go-to market, according to a statement.

"Mark [Roberge] and Jay [Po] immediately developed a deep contextual understanding of Klara, and pinpointed our growth opportunities," cofounder Dr. Simon Lorenz said in a statement. "They've already helped us heighten our focus to achieve more sustainable ARR growth and improve customer success, and are also working with our team to align our marketing, sales, and customer success strategies. That way, we can serve individual customer segments more effectively."

...

On your Marq, get set, go. Garmin has launched a line of high-end smartwatches (ranging from more than $1,500 to $2,500) aimed at particular activities. The Marq line includes the Captain, for sailors; the Driver, for car racers; the Aviator, for pilots; the Expedition, for hikers and explorers; and the Athlete, for, well, athletes. Each device has its own features but also includes heart rate and a pulse oximetry sensors. DC Rainmaker has an in-depth look at the devices.

...

Crackdown on mail-order abortion pills raises questions. The FDA has cracked down on two online retailers selling medical abortion pills, Vox reports. While the agency maintains that the move is part of a broader crackdown on illegal online drug sales, it does come at a time when the national debate on abortion, including telemedicine abortion, is fraught. One of the companies in question, AidAccess, was using an Indian pharmacy to get around prescription restrictions that specifically target abortion drugs.